X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer. * Evidence of positive ALK. * Patients must have demonstrated progression during or after crizotinib treatment. * Age 18 years or older at the time of informed consent. * Eastern cooperative oncology group performance status (ECOG PS) of 0-2 * Measurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1). * Asymptomatic CNS metastases do not require the use of steroids or anticonvulsants. * Willingness and ability to comply with the trial and follow-up procedures. * Ability to understand the nature of this trial and give written informed consent. Exclusion Criteria: * Prior use of ALK TKIs with the exception of crizotinib. * Patients currently receiving cancer system therapy. * Use of an investigational drug within 4 weeks prior to the first dose of study drug. * Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications. * Patients with a known allergy or delayed hypersensitivity reaction to drugs.